scholarly journals Patient‐reported pain severity and health‐related quality of life in patients with multiple myeloma in real world clinical practice

2021 ◽  
Author(s):  
Heinz Ludwig ◽  
Abigail Lucy Bailey ◽  
Andrea Marongiu ◽  
Keerun Khela ◽  
Gary Milligan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Myeloma ◽  
Clinical Practice ◽  
Real World ◽  
Pain Severity ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

scholarly journals Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings

2020 ◽  
Vol 29 (10) ◽  
pp. 2651-2660
Author(s):  
Richard W. Joseph ◽  
Frank Xiaoqing Liu ◽  
Alicia C. Shillington ◽  
Cynthia P. Macahilig ◽  
Scott J. Diede ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Real World ◽  
Repeated Measures ◽  
Advanced Melanoma ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Eq Vas

Abstract Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinical practice. Methods A prospective US observational study enrolled adult AM patients initiating first-line PEMBRO or IPI + NIVO between June 2017 and March 2018. Endpoints included the QLQ-C30 global health score (GHS) and EuroQol visual analog scale (EQ-VAS) scores. Mean changes were compared using repeated measures mixed-effects models and are presented covariate adjusted. Results 225 PEMBRO and 187 IPI + NIVO patients were enrolled. From baseline through week 24, PEMBRO was associated with 3.2 mean GHS score increase (95% CI 0.5, 5.9; p = .02), while no change was observed with IPI + NIVO; 0.2 (95% CI − 2.6, 3.0; p = 0.87). Among objective treatment-responders, GHS scores associated with PEMBRO increased 6.0 (95% CI 3.1, 8.8; p < .0001); IPI + NIVO patients increased 3.8 (95% CI 0.8, 6.9; p = .01). In treatment non-responders, IPI + NIVO was associated with GHS/QoL deterioration of − 3.7 (95% CI − 6.8, − 0.6; p = .02), PEMBRO non-responders demonstrated no change; 0.7 (95% CI − 2.3, 3.7; p = 0.6). Between treatments, PEMBRO patients increased 2.6 greater in EQ-VAS (95% CI 0.6, 4.5; p = .01) vs IPI + NIVO at 24 weeks. Conclusions PEMBRO was associated with better 24-week QoL compared to IPI + NIVO in actual clinical practice settings. Real-world data has known limitations, but with further confirmation these results may have implications for treatment selection.

scholarly journals Health‐related quality of life of patients with multiple myeloma: A real‐world study in China

2020 ◽  
Vol 9 (21) ◽  
pp. 7896-7913
Author(s):  
Xiaozhe Li ◽  
Junru Liu ◽  
Meilan Chen ◽  
Jingli Gu ◽  
Beihui Huang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Myeloma ◽  
Real World ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals The use of real-world effectiveness measurements in clinical settings at Helsinki University Hospital: a systematic literature review

2020 ◽  
Vol 9 (5) ◽  
pp. 321-326
Author(s):  
Kati Koskinen ◽  
Maija Hytönen ◽  
Pirjo Räsänen
Keyword(s):  
Quality Of Life ◽  
Real World ◽  
Real Life ◽  
University Hospital ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related ◽  
Quality Of Life Instruments

Aim: Patient reported outcomes collected alongside clinical trials do not reflect real-world effectiveness (RWE). This review assessed the use of RWE measurements in routine clinical treatment and the instruments applied to collect that data. Materials & methods: The RWE articles published from HUS (Helsinki University Hospital) were extracted from several databases. Results: Out of 170 eligible articles, generic health-related quality of life instruments were used in 87 (51.2%) and disease-specific health-related quality of life instruments in 58 (34.1%) articles as a primary measurement. Most of the articles pertained to surgery, gynecology and pediatric surgery. Conclusion: The number of articles assessing RWE is very limited compared with all the articles published from HUS. Thus, we still have limited information about the effectiveness of the treatment in real life.

Patient-reported, health-related, quality of life after stroke thrombectomy in clinical practice

Neurology ◽  
2020 ◽  
Vol 95 (12) ◽  
pp. e1724-e1732 ◽  
Author(s):  
Milani Deb-Chatterji ◽  
Alexander Konnopka ◽  
Fabian Flottmann ◽  
Hannes Leischner ◽  
Jens Fiehler ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Functional Outcome ◽  
Health Related Quality ◽  
Patient Reported ◽  
Health Domains ◽  
Related Quality ◽  
Health Related ◽  
Reported Health

ObjectiveTo determine patient-reported health-related quality of life (HRQOL) after stroke thrombectomy in clinical practice and to identify predictors of better HRQOL by analyzing data of 504 consecutive patients treated in a large university stroke center.MethodsAll patients with stroke treated by thrombectomy (June 2015–October 2018) were prospectively enrolled in this observational study. At 90 days, functional outcome was assessed by the modified Rankin Scale (mRS) and patient-reported HRQOL was assessed by the EuroQol Group 5-Dimension (EQ-5D) self-report questionnaire, consisting of 5 health domains. The EQ-5D utility index (EQ-5D-I) score (−0.594 to 1.00, with higher values indicating better HRQOL) was calculated. Linear regression analysis was applied to identify predictors of better HRQOL (higher EQ-5D-I score).ResultsOf 504 patients (median age 76 years, 51.8% female), the mean EQ-5D-I score was 0.39 (SD 0.44). The proportion of stroke survivors who reported complaints in the different domains decreased from 66% in Usual Activities to 57% in Mobility, 50.4% in Self-Care, 41.7% in Pain/Discomfort, and 40.8% Anxiety/Depression. Lower age, lower prestroke mRS score, lower baseline NIH Stroke Scale score, higher Alberta Stroke Program Early CT Score, concomitant thrombolysis therapy, and a successful recanalization were independent predictors of better HRQOL.ConclusionsPatient-reported HRQOL provides a more comprehensive assessment of stroke outcome than the mRS score. Health domains involving motor function most frequently showed complaints in HRQOL after stroke thrombectomy, while a large proportion of patients did not report any complaints across the different health domains. Predictors of better HRQOL closely match the predictors of better functional outcome measured by the mRS in other thrombectomy studies.

Sign in / Sign up

Export Citation Format

Share Document